Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.48 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7158491 | 1.00 | CNR1 (0.48) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7158488 | 1.00 | CNR1 (0.48) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6601518 | 0.91 | CNR1 (0.53) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6600466 | 0.77 | CNR1 (0.49) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4484123 | 0.75 | NOTUM (0.54) | CNR1CNR2NOTUMCHRNA7 | |
| SCHEMBL13717376 | 0.74 | CNR1 (0.71) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13602554 | 0.74 | CNR1 (0.71) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6464405 | 0.74 | CNR1 (0.71) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13717141 | 0.74 | CNR1 (0.71) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13717726 | 0.74 | CNR1 (0.71) | CNR1CNR2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | PGC, GIPR, GPR119 | CNR1 118/4885CNR2 190/4885TAS1R3 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.